

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Gender: **Female** | Birth year: **1946** | WHO: **0**

Tumor: **Colorectum (cecum) carcinoma** | Lesions: **Lung, Peritoneal** | Stage: **IV**

Clinical summary

| | | |
|-------------------------------------|------------------------------------------------------------------------------------------------------|-------------------------------------|
| Relevant systemic treatment history | None | |
| Relevant other oncological history | 11/2021 | Hemicolecction right (Cecum) |
| Previous primary tumor | Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active) | |
| Relevant non-oncological history | 1/2019 | Cerebrovascular accident |

Standard-of-care options considered potentially eligible

| Treatment | Literature efficacy evidence | Warnings |
|----------------|---------------------------------------------|----------|
| FOLFIRI | PHASE-3-CRC | |
| | PFS: 10.0 months (95% CI: 10.0-12.0) | |
| | OS: 25.0 months (95% CI: 25.0-30.0) | |

Phase 2/3+ trials in NL that are open and potentially eligible (0 trials)

| Trial | Cohort | Molecular | Sites | Warnings |
|---------------------------------|------------------|------------------|--------------------|----------|
| KRAS-G12D-TRIAL | <i>KRAS G12D</i> | <i>KRAS G12D</i> | <i>UMC Utrecht</i> | |

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

Molecular Details

NGS & MSI Panel (15-Jan-2023)

| | |
|------------------------------|--------------|
| Biopsy location | Lung |
| Tumor mutational burden | TMB 8 mut/Mb |
| Microsatellite (in)stability | Stable |
| Driver mutations | KRAS G12D |

IHC results

| | |
|-------|---------------------|
| Ki67 | Positive, score 90% |
| PD-L1 | Score < 50% |

Efficacy evidence

Standard of care options considered potentially eligible


The following standard of care treatment(s) could be an option for this patient. For further details per study see 'SOC literature details' section in extended report.

| Treatment | Literature efficacy evidence | | | | | | | | | | | | |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|----------------------------------|------------------------|-------------------------------------------|-----------|-------------------------------|------------------|----------------------------------------------|---------------------------|--------|-----------------|-----------------------|
| FOLFIRI | <p>PHASE-3-CRC</p> <p>Patient characteristics:</p> <table><tbody><tr><td>WHO/ECOG</td><td>0: 100, 1: 80, 2: 20, 3: 0, 4: 0</td></tr><tr><td>Primary tumor location</td><td>Left: 145, Both or unknown: 10, Right: 45</td></tr><tr><td>Mutations</td><td>KRAS exon 2 wild-type 200/200</td></tr><tr><td>Metastatic sites</td><td>Liver only: 58 (32.0%), Lung only: 10 (6.0%)</td></tr><tr><td>Previous systemic therapy</td><td>35/200</td></tr><tr><td>Prior therapies</td><td>Adjuvant chemotherapy</td></tr></tbody></table> <p>Median PFS: 10.0 months (95% CI: 10.0-12.0)</p> <p>Median OS: 25.0 months (95% CI: 25.0-30.0)</p> | WHO/ECOG | 0: 100, 1: 80, 2: 20, 3: 0, 4: 0 | Primary tumor location | Left: 145, Both or unknown: 10, Right: 45 | Mutations | KRAS exon 2 wild-type 200/200 | Metastatic sites | Liver only: 58 (32.0%), Lung only: 10 (6.0%) | Previous systemic therapy | 35/200 | Prior therapies | Adjuvant chemotherapy |
| WHO/ECOG | 0: 100, 1: 80, 2: 20, 3: 0, 4: 0 | | | | | | | | | | | | |
| Primary tumor location | Left: 145, Both or unknown: 10, Right: 45 | | | | | | | | | | | | |
| Mutations | KRAS exon 2 wild-type 200/200 | | | | | | | | | | | | |
| Metastatic sites | Liver only: 58 (32.0%), Lung only: 10 (6.0%) | | | | | | | | | | | | |
| Previous systemic therapy | 35/200 | | | | | | | | | | | | |
| Prior therapies | Adjuvant chemotherapy | | | | | | | | | | | | |

ACTIN Report (research use only)


PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025





All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

SHAP values for treatment: No Treatment



SHAP values for treatment: FOLFIRI





Resistance evidence

| Treatment | Mutation | Evidence source | Evidence level | Found in molecular analysis |
|-----------|-----------|-----------------|----------------|-----------------------------|
| FOLFIRI | GENE S11C | [1] | D | Yes |

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

ACTIN Report (research use only)

PATIENT
EXAMPLE-CRC-01

REPORT DATE
17-Sep-2025

Clinical Details

Clinical summary

| | | |
|-------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------|
| Relevant systemic treatment history | None | |
| Relevant other oncological history | 11/2021 | Hemicolectomy right (Cecum) |
| Previous primary tumor | Skin squamous cell carcinoma (diagnosed 6/2016, last treatment 8/2016, considered non-active) | |
| Relevant non-oncological history | 1/2019 | Cerebrovascular accident |

Patient current details (05-Mar-2023)

| | |
|----------------------------------|----------------------------------------|
| Unresolved toxicities grade => 2 | None |
| Known allergies | Morphine |
| Recent surgeries | 12-Nov-2021 Hemicolectomy right |

Tumor details (05-Mar-2023)

| | |
|--------------------|--------------------------------|
| Measurable disease | Yes |
| Known lesions | Lung, Peritoneal |
| Unknown lesions | Lymph node |
| No lesions present | CNS, Brain, Liver, Bone |

Active medication details

| Medication | Administration route | Start date | Stop date | Dosage | Frequency |
|------------|----------------------|------------|-----------|--------|-----------|
| None | | | | | |

Blood transfusions

| Product | Date |
|----------------------|-------------|
| ERTHROCYTES_FILTERED | 10-Jan-2023 |

Trial Matching Details

Trials and cohorts that are potentially eligible, but are closed (2 cohorts from 1 trial)

| Trial | Cohort | Molecular | Sites | Warnings |
|------------------------------------|-------------------------------------|-----------|-------|-----------------------|
| METC 01 IEMOEN | <i>Applies to all cohorts below</i> | None | | Has not exhausted SOC |
| | Dose escalation - monotherapy | | | |
| | Dose expansion - monotherapy | | | |

Trials and cohorts that are considered ineligible (2 cohorts from 1 trial)

| Trial | Cohort | Molecular | Ineligibility reasons |
|------------------------------------|-------------------------------------------|-----------|----------------------------------------|
| METC 02 KAYRAS | <i>Applies to all cohorts below</i> | KRAS G12D | PD-L1 expression below minimum of 50.0 |
| | Dose expansion - monotherapy - Colorectum | | |
| | Dose expansion - monotherapy - NSCLC | | No lung non-small cell carcinoma |

Trials and cohorts that are not evaluable or ignored (0 trials)

| Trial | Cohort | Molecular | Sites | Configuration |
|-------|--------|-----------|-------|---------------|
| None | | | | |